The trough:peak (T:P) ratio serves as an index of efficacy of antihypertensive drugs with respect to their dose and dose interval. There is no consensus regarding the method for the calculation of the T:P ratio. We assessed the influences of curve smoothing, the average fall in 24-h mean arterial pressure (MAP) and the length of the peak effect period on the result of T:P ratio calculation. Forty-two patients with essential hypertension (aged 27-81 years; 20 males) had a 24-h ambulatory blood pressure (BP) measurement on two occasions. The first was performed at baseline, the second after 12 weeks of treatment with a ␤-blocker, angiotensin-converting enzyme inhibitor, calcium slowchannel blocker, diuretic or a centrally acting drug, all taken once daily. BP data were analysed both by Fourier analysis (FA) with four harmonics and by time block analysis (TBA). The peak effect was defined as the maximum drop in MAP over a period of 0 to 3 h following drug intake at any time in the 24 h, and the trough effect as the fall in MAP over the last 2 h of the dose interval. FA gave higher T:P ratio values than TBA (0.51 vs 0.43;
Introduction
Guidelines of the US Food and Drug Administration (FDA) indicate that the efficacy of an antihypertensive drug relative to its proposed dose interval may be expressed as the trough:peak (T:P) ratio, in which the effect of the drug at the end of the dose interval (trough) should be greater than 50% of the peak effect. 1 Factors such as circadian variability, placebo effects, standardised conditions, individual calculations and multiple blood pressure (BP) readings are regarded as essential for reproducible calculation of T:P ratios. Currently, 24-h ambulatory BP monitoring (ABPM) is increasingly used in the evaluation of antihypertensive drugs. However, to date, there is no consensus as to the manner in which T:P ratios should be determined from ABPM P Ͻ 0.05) and the variability of the results was reduced by FA (FA: 0.49-0.52; TBA: 0.35-0.46). A greater fall in 24-h MAP was associated with a higher T:P ratio (r ‫؍‬ 0.42, P Ͻ 0.02; TBA: r ‫؍‬ 0.31, P ‫؍‬ 0.09). Half of the patients whose fall in 24-h MAP after treatment was Ͻ10 mm Hg, had higher trough BP values, resulting in negative T:P ratios. With increasing length of the peak period, the calculated peak effect was reduced and the T:P ratio increased (both FA and TBA: P Ͻ 0.001). The mean trough responses during the last 2 h of the dose interval were similar after TBA and FA.
Based on these data, we recommend the use of FA for calculation of T:P ratios, especially when the magnitude of the antihypertensive effect is small. We also suggest using peak-and trough-effect periods of 2 h each. Whenever T:P ratios are calculated, the method used for curve smoothing and the length of peak-and trougheffect periods should be specified in order to obtain meaningful results. T:P ratios need to be interpreted individually together with the magnitude of the antihypertensive drug effect and the circadian BP profile.
data. [2] [3] [4] [5] [6] In consequence, values for T:P ratios reported for the same drug vary greatly according to the method of calculation. [7] [8] [9] [10] BP is subject to short-lived fluctuations, linked to factors such as physical activity, mental stress and meal times. These fluctuations influence the calculation of the antihypertensive response to drugs. This influence is more marked if the overall antihypertensive effect of a drug is small and more readily obscured by random variations in BP, resulting in a large error in the T:P ratio. It is impossible to eliminate all random variability by standardisation of activities in an out-patient setting. However, the problem may be overcome partly by smoothing of the BP curve. [11] [12] [13] [14] Since BP follows a circadian course which may be influenced throughout by long-acting antihypertensive drugs, modelling of the 24-h BP by Fourier analysis (FA), which amplifies long-term relative to short term variations, may improve the ratio estimates. Extending the peak or trough time period may likewise lessen random variation.
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In this study, we examined the impact of smoothing the BP curve by a Fourier series and a standard time block analysis (TBA) on the calculated value of the T:P ratio. In addition, the influence of the BPlowering effect of drug therapy and the variation of the time period during which the peak effects are assessed on T:P ratio calculation was investigated.
Materials and methods

Patients and study design
The study population was selected from 50 patients referred to the out-patient clinic for the evaluation of hypertension, if mean daytime (8 am to 11 pm) mean BP (MAP) exceeded 100 mm Hg, night-time fall in BP was у10% and secondary hypertension was excluded. Forty-two patients aged 49 ± 2 years (range 27-81 yr; 20 males; 21 previously untreated) were selected for study on this basis. A first 24-h ABPM (ABPM-1) without treatment was performed for diagnostic purposes. 15, 16 Patients were described one of the drugs shown in Table 1 on clinical grounds and a second ABPM (ABPM-2) was undertaken after 3 months. The study was approved by the hospital's Ethics Committee.
Ambulatory blood pressure measurements and data processing ABPM was performed using the SpaceLabs 90207 BP monitor (SpaceLabs Inc., Redmond, WA, USA). It was programmed to obtain measurements every 15 min from 7 am to 11 pm and every 30 min from 11 pm to 7 am. Systolic readings of Ͻ70 and Ͼ250 mm Hg, diastolic readings of Ͻ40 and Ͼ150 mm Hg, pulse pressure readings of Ͻ15 and Ͼ150 mm Hg and heart rates of Ͻ30 or Ͼ200 beats/min were discarded.
Measurements were made on typical week-days and patients were discouraged from taking unusual exercise. They were carefully instructed to rise between 6.30 and 7 am, take their medication about 1 h later, report to the hospital between 8 and 8.30 am and retire at 11 pm. Compliance with this instruction was verified by inspecting diary entries. The BP recording had to span the full 24-h period and at least 80% of the data had to be valid or the record was discarded. Spacelabs software was used to obtain raw data and a commercial spreadsheet program was used for calculating hourly averages. FA with four harmonics was applied to the raw data to obtain smoothed BP profiles. 11, 12 We then synchronized the data and subtracted MAP after treatment (ABPM-2) from that before treatment (ABPM-1) in order to determine the peak and trough treatment effects. The peak effect was defined as the maximum fall in pressure over a period of either 0-3 h (FA) or 1-3 h (TBA), at any time in the 24-h period, using moving averages. The trough effect was defined as the drop in MAP over the last 2 h before drug administration. T:P ratios were calculated from the trough and peak effects.
Statistical analysis
All statistical procedures were performed by the SPSS statistical program (SPSS Inc., Chicago, IL, USA). The effect of drug treatment is expressed as the mean change in daytime, night-time and 24-h MAP (±s.e.m). The percentage change in peak effect between two time periods is given as mean (±s.e.m). As the individual T:P ratios are not normally distributed, 3 they are represented by median values and the 5th and 95th percentile interval (PI). The Wilcoxon signed-ranks test was used to compare T:P ratios after analysis of ABPM data by either TBA or FA, and for post-hoc analysis after ANOVA (see below). Student's t-test was used for all other comparisons. Friedman two-way ANOVA was performed to compare T:P ratios calculated with various peak-effect periods for both time block and Fourieranalysed data. The relationship between T:P ratio values and drug-induced fall in 24-h MAP was determined by the Spearman rank correlation test. P Ͻ 0.05 was considered statistically significant.
Results
Effects on blood pressure
None of the drugs affected the circadian BP pattern; during ABPM-2 all patients continued to show a nocturnal fall in BP of at least 10% (12.2% (±1%) at ABPM-1, 13.4% (±1.3%) at ABPM-2). Figure 1 shows BP curves for one subject after TBA ( Figure 1A ) and FA ( Figure 1B ). The BP profile obtained from hourly mean BP values contains several unlikely outliers, which were 'smoothed out' by FA. Averaged ambulatory BP values during daytime, night-time and 24 h are listed in Table 2 . The BPlowering effect of individual drugs used is not shown. The maximum drop in BP (peak effect) was at 11 ± 0.8 hours (range 6-20 hr) after drug intake. The overall drug-induced decrease in 24-h MAP in the entire study population was 15 ± 2 mm Hg (range 0-35; P Ͻ 0.0001), with a similar antihypertensive effect during day-and night-time (16 ± 2 and 15 ± 2 mm Hg, respectively). Table 2 Ambulatory blood pressure before and after drug intervention (n = 42). Data are expressed as mean ± s.e.m.
139 ± 2.5 85 ± 1.6 103 ± 1.7 118 ± 2.5 71 ± 1.7 88 ± 1.9
ABPM, ambulatory blood pressure monitoring; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure (all mm Hg).
Calculation of T:P ratio: Fourier vs time block analysis
T:P ratios were first calculated from peak-and trough effects assessed during a 2-h period after either TBA or FA. Although most T:P ratios were positive, some negative values were also found (see below). Figure 2 shows the relationship between T:P ratios calculated by TBA and FA. FA rendered higher values than TBA. The median T:P ratios for Figure 2 Relationship between T:P ratios calculated after time block and Fourier analysis. In patients with a positive T:P ratio, Fourier analysis gave higher values than time block analysis, on average (P Ͻ 0.05). Peak effect data in the figure were obtained over a 2-h period; trough effect was measured during the last 2 h of the dose interval.
the whole group were 0.51 (PI, −0.34 to 0.98) after FA, and 0.43 (PI, −0.27 to 0.99) after TBA (Table 3 ; P Ͻ 0.05). For patients with positive T:P ratios, the median T:P ratio values were 0.64 (PI, 0.17 to 0.99) after FA and 0.51 (PI, 0.18 to 1.0) after TBA (P Ͻ 0.05). For negative T:P ratios, no significant differences were found between the methods of analysis. Individual data were, however, less stable after TBA than after FA (Table 3 and next paragraph). Figure 3 shows the correlation between T:P ratio values and the magnitude of the antihypertensive drug-effect. For all 42 subjects, a significant positive correlation was found between T:P ratio values and treatment-induced changes in 24-h MAP, irrespective of the method of analysis (for TBA: Spearman r = 0.49, P Ͻ 0.01; for FA: Spearman r = 0.55, P Ͻ 0.001). Approximately half of the patients who had an average fall in 24-h MAP of less than 10 mm Hg, had negative T:P ratios by either analysis (Figure 3 ). Table 3 lists the T:P ratio values based on peak effect periods of 1-3 h (after TBA) and of 0-3 h (after FA). In Table 4 peak effects during time periods of 1-3 h are shown for TBA and during periods of 0-3 h for FA. When the peak effect for the various time inter- Table 3 Effect of the duration of the peak effect period on the T:P ratio. Ratio values are expressed as the median with 5th and 9th percentile interval values. T:P Ͻ 0 designates ratios that were negative in any of the chosen time periods vals was computed by TBA, the mean BP values were different from the median BP values whereas mean and median peak effects calculated from FAderived data during forementioned time intervals were almost identical (Table 4) . After both TBA and FA the peak effect decreased with lengthening of the peak effect period (both P Ͻ 0.0001). Lengthening of the peak effect period from 1 to 2 h resulted in a mean decrease in peak effect of 14.6% (±1.7) after TBA, in comparison to a decrease of 3.2% (±0.2) after FA P Ͻ 0.0001). Further lengthening of the peak effect period to 3 h showed an additional decrease in the peak effect of 10.4% (±1.4) after TBA and 4.4% (±0.3) after FA (P Ͻ 0.001) ( Table 5 ). Thus, after TBA, the individual T:P ratios are more influenced by changes in the peak effect period than after FA (Tables 3 and 5 ).
Calculation of T:P ratio: influence of fall in blood pressure
Calculation of T:P ratio: influence of length of peak effect period
Calculation of T:P ratio: length of trough effect period
Although the trough effect period is more strictly defined than the peak effect period, ie, the last time interval preceding the (next) dosing of a drug, the Table 5 Influence of change of peak effect period on the mean percentage change in peak effect, according to T:P ratios above and below zero, and overall. 'T:P Ͻ 0' indicates ratios that were negative in any of the chosen time periods
Change in effect period (h)
Time block analysis Fourier analysis
% change in peak T:P (n = 42) 14.6(±1. length of this interval and the number of data points needed to reliably estimate the trough effect are usually not specified. 3, 5 The mean trough responses during the last 2 h of the dose interval were similar after TBA and smoothing by FA (TBA: −12.8 (±2.0); FA: −12.8 (±1.8) mm Hg). In contrast to BP changes at peak, the mean and median BP changes at trough, obtained by either method of analysis, were practically identical (TBA: median −11.5 (PI, −34.6 to 7.4); FA: median −12.5 (PI, −32.8 to 5.6) mm Hg), indicating a normal distribution.
Negative T:P ratios
As stated above, in some patients, despite a fall in BP after treatment, a negative value of T:P ratio was found, which was invariably due to a higher value during the trough period at ABPM-2 than ABPM-1. Negative values were found in 8 to 10 out of 42 patients after TBA (depending on the length of the peak effect period) and in 6 patients after FA. The finding of negative T:P ratios may be explained by random variations occurring during a time period when the actual BP difference is small. Accordingly, negative T:P ratio values were less frequent after curve smoothing by FA than by TBA (Figures 2 and  3 ) and negative T:P ratio values were uncommon, for both methods of analysis, when the average fall in 24-h MAP was greater than 10 mm Hg ( Figure 3A and 3B). Negative T:P ratios could sometimes be attributed to a shift in time of the circadian rhythm. In case of a pronounced early morning rise in BP, which occurs at an earlier time point during ABPM-2 than during ABPM-1, a higher BP will be found during the trough period.
Discussion
Conventionally, calculation of the T:P ratio was based on auscultatory BP measurements performed under standardized conditions at some point after dosing and just before the next dose. Conventional BP measurements, however, allow only a limited number of BP readings, and as the peak effect is measured at more or less arbitrarily chosen time points, coinciding with the peak concentrations of the drug, this method may yield erroneous peak effect values. 17, 18 These methodological problems are partly overcome by the use of 24-h ABPM. 3, 19 However, there is no consensus with regard to the method of analysis of ambulatory BP profiles, which would provide reliable data for the calculation of the T:P ratio.
Several methods of analysis of ABPM have been recommended. [1] [2] [3] 7, 20 Generally, the mean or median daytime or night-time BP is used in the assessment of antihypertensive drug therapy in groups of patients. 7, 20 A potential problem of group-averaged BP values is that periods of hypertension in individuals may remain undetected. Therefore, it is necessary to model the 24-h BP curve in each individual. When studying individuals, some smoothing of the diurnal BP profile is necessary to abolish outliers and to allow a more precise estimation of peak-and trough effects. 11, 14 Two methods, TBA and FA, have been suggested for smoothing. 3, [11] [12] [13] To date, the impact of these methods on the calculation of T:P ratios has not been compared. When Fourier transformation is used, the rate of smoothing depends on the number of harmonics. [11] [12] [13] Chau et al 13 found that a Fourier model with three to five harmonics was sufficient to describe the BP curve. Recently, a Fourier series with four harmonics, which allows for varying intervals between successive BP readings, was described. This FA adequately transforms ambulatory BP data into a curve which remains mathematically similar to, but less 'noisy' than, the raw data. 11, 12 The circadian BP profile is characterised by gradual changes throughout the 24-h period. Similarly, the BP-lowering effect of once-daily given drugs shows rather slow-onset long-term variations. In view of this, FA, which amplifies long-term variations rather than short-term 'noise', is expected to be suitable for modelling the BP curve and consequently, for improving the calculation of the T:P ratio. The method used by us is appropriate when recorders are programmed to obtain measurements more frequently during the day than during the night. In spite of the advantages, FA may result in apparent 'oversmoothing' of the BP profile, and consequently in underestimation of the peak effect and a high T:P ratio. The same may also occur with TBA if an inappropriately long averaging interval is chosen. 5, 7 Another way to minimise the influence of outliers is to increase the length of the period during which the peak effect is evaluated. Zanchetti et al 3 have described various ways in which the peak effect can be determined from 24-h ambulatory BP data. Using a TBA, these authors found that measurement of the peak effect during a longer time period flattens the effect but reduces the imprecision observed when the effect period is as short as 1 h. The investigators do not give final recommendations with respect to the choice of the peak effect period. 3 Moreover, the possible influence of the method of BP data analysis on the determination of peak effect was not mentioned. Our data indicate that, when BP data are analysed by TBA, variation of the peak effect period results in unpredictable changes of the T:P ratio, whereas after smoothing by FA, lengthening of the period gradually decreases the peak effect, with a concomitant increase in median T:P ratios. Recently, using a TBA, Omboni et al 21 have demonstrated in a large population that BP changes at peak are normally distributed. In our study, mean and median BP changes were identical after FA only. This discrepancy may be explained by the limited number of patients in our study, the presence of outliers and the use of various antihypertensive drugs. Our suggestion that the peak BP effect should be evaluated over a 2-h period is in line with the recommendation of Omboni et al. 21 These authors also found that a time window of 2 h is the best compromise between magnitude and reproducibility of peak effect. 21 Different factors should be considered when choosing the length of the trough effect period. When the trough effect is measured during a prolonged interval before drug dosing, due to a physiological fall in night-time BP, the drug-induced BP lowering effect might be obscured. 6 However, Omboni et al 21 found similar BP values when the trough effect was assessed by averaging the last 1, 2 or 4 h of the recording. As their patients took the active drug between 9 and 10 am and ABPM was started at about the same time, it is likely that the 2-h and 4-h trough BP values were affected by the physiological BP changes taking place after wakening. A different timing could be used to circumvent this problem. For example, the patient could take the drug at 10 pm or, alternatively, a few hours after rising (eg, 11 am after rising at 8 am) while trough BP changes are determined from 9-11 am. As this alternative schedule has to be implemented days before the ABPM, it may not be practicable. In addition, interference with the patient's daily timing of drug ingestion may cause unnecessary confusion. Therefore, when 24-h ABPM starts early in the morning, assessment of the trough effect during 2 h before dosing, ie partly during the supine (sleeping) and partly during the standing (waking) period, seems a reliable and achievable compromise.
This study does not include a placebo-treated group. It has been shown that 24-h average BP is not reduced by placebo. 3, 22, 23 A small decrease in BP, however, may be observed during the first 2-6 h of ambulatory monitoring in placebo-treated groups. 21, 23, 24 This effect seems inconsistent and, in contrast to the treatment-induced effect, is not normally distributed. 21 In our patients, the peak effect occurred on average 11 h after drug intake. A similar time-to-peak was found by Staessen et al 24 using lisinopril as a single antihypertensive agent. Some authors claim that placebo correction reduces the peak effect and consequently, increases the T:P ratio of a single antihypertensive drug.
6,21,24,26 According to Omboni et al 21 this effect is small and placebo correction may even worsen the scatter in the T:P ratio. In view of this, and taken into account that the BP values used for the actual calculation of T:P ratio are obtained at time points when the placebo effect has no great impact, we feel that placebo treatment is not required when T:P ratios are calculated from ABPM data.
Still another factor may affect BP values during the first hours of 24-h ABPM. This phenomenon, which shows a rise in BP, is probably due to an arousal reaction in response to the first few BP measurements which subsides with further measurements due to habituation to the procedure. In view of this, it has been argued that ABPM recordings should be preferably performed during 26 h and that the first 2 h should be excluded from the summary analyses. 25 In the daily clinical practice, however, these prolonged ABPM may not be achievable.
A relationship was found between the mean 24-h drug-induced fall in BP and the T:P ratio. Patients who had a mean decrease of 24-h MAP of more than 10 mm Hg, had positive T:P ratios after both TBA and FA. Negative ratios were primarily observed in subjects who showed little response to drug therapy. Others have suggested that T:P ratio values are more consistent and normally distributed, when only responders to the drug are included in the analysis. Omboni et al 21 found that in patients whose peak MAP fell by at least 12 mm Hg (ie, changes in systolic/diastolic BPs of 15/10 mm Hg or more) T:P ratios were normally distributed, whereas T:P ratios from patients whose peak changes in MAP equalled 6 or 8 mm Hg changes followed a non-normal distribution. Although these effects may be of clinical relevance, these patients were considered nonresponders. Exclusion of non-responders from the final analysis, on average, results in a reduction of 30-40% of the original population and consequently, a loss of randomisation. 3, 21 In view of this, exclusion of non-responders seems undesirable. Alternatively guidelines for the unequivocal definition of non-responders are required. In the absence of such guidelines we analysed the data of all patients, irrespective of the antihypertensive drug effect.
To date, only a few studies mention the existence of negative values for T:P ratios. 3, 17, 21, 24 As in our method of analysis the peak effect is defined as the greatest difference in BP between the treated and untreated condition which can be found at any point of the 24-h curves, a fall in BP will always be detected and the trough effect can never be greater than peak, and the T:P ratio cannot exceed unity. In case of little effect of the drug, the trough effect, which is determined at a fixed time interval at the end of the dosing interval, may well be greater without treatment due to random variations, resulting in a positive trough value. The best way to deal with negative ratios in a study population may be to convert them to zero, which indicates that the drug is no longer active. This method may obviate the need to exclude non-responders.
We are aware of some limitations of our study.
First of all, we used different antihypertensive drugs, which may differ with respect to their pharmacodynamics. This may have contributed to the large scatter of the T:P ratios found in TBA. Our findings need to be confirmed in studies with individual drugs. Also, the number of patients was small and perhaps insufficient to permit extensive conclusions. In addition, the absence of a placebotreated group and possible overmodelling by FA may have affected the absolute values of individual T:P ratios. These limitations, however, seem of lesser importance as the main objective of this study was to evaluate the application of two methods of analysis of ABPM in the calculation of the T:P ratio in an average hypertensive out-patient population, and to further improve the methodology of T:P ratio calculation, rather than to compare absolute T:P ratio values of antihypertensive drugs. Nonetheless, the occurrence of overmodelling remains a problem. While smoothed curves should be used to obtain a 'general picture' they cannot be used to confidently rule out an inadvertent drop in BP in the individual patient.
In summary, since the main goal of antihypertensive drug treatment in the individual patient is to control BP evenly for 24 h, calculation of individual T:P ratios is more appropriate than estimating the ratio from group BP means. In order to obtain meaningful results from each individual, curve smoothing is necessary to diminish variability. Our finding that the T:P ratio was less dependent on the chosen length for the peak effect period after FA than after TBA indicates that FA provides more stable and consistent results. As a recommendation we would favour the use of FA with four harmonics and trough and peak periods of 2 h each. Negative T:P ratios should be converted to zero. In addition, the individual BP-lowering effect as well as the BP profile should be taken into account when interpreting the meaning of the T:P ratio. Further studies are needed to define more precisely the reproducibility of the T:P ratio in individual patients.
